Claims
- 1. A method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.
- 2. The method of claim 1, wherein the biological sample comprises isolated nucleic acids.
- 3. The method of claim 2, wherein the nucleic acids are mRNA.
- 4. The method of claim 2, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.
- 5. The method of claim 1, wherein the polynucleotide comprises a sequence as shown in Tables 1-25.
- 6. The method of claim 1, wherein the polynucleotide is immobilized on a solid surface.
- 7. The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat breast cancer.
- 8. The method of claim 1, wherein the patient is suspected of having breast cancer.
- 9. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.
- 10. The nucleic acid molecule of claim 9, which is labeled.
- 11. An expression vector comprising the nucleic acid of claim 9.
- 12. A host cell comprising the expression vector of claim 11.
- 13. An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.
- 14. An antibody that specifically binds a polypeptide of claim 13.
- 15. The antibody of claim 14, further conjugated to an effector component.
- 16. The antibody of claim 15, wherein the effector component is a fluorescent label.
- 17. The antibody of claim 15, wherein the effector component is a radioisotope or a cytotoxic chemical.
- 18. The antibody of claim 15, which is an antibody fragment.
- 19. The antibody of claim 15, which is a humanized antibody
- 20. A method of detecting a breast cancer cell in a biological sample fromi a patient, the method comprising contacting the biological sample with an antibody of claim 14.
- 21. The method of claim 20, wherein the antibody is further conjugated to an effector component.
- 22. The method of claim 21, wherein the effector component is a fluorescent label.
- 23. A method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of:
(i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.
- 24. A drug screening assay comprising the steps of
(i) administering a test compound to a mammal having breast cancer or a cell isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. S No. 60/263,965, filed Jan. 24, 2001; U.S. S No. 60/265,928, filed Feb. 2, 2001; U.S. Ser. No. 09/829,472 filed Apr. 9, 2001; U.S. S No. 60/282,698, filed Apr. 9, 2001; U.S. S No. 60/288,590, filed May 4, 2001; and U.S. S No. 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.
Provisional Applications (5)
|
Number |
Date |
Country |
|
60263965 |
Jan 2001 |
US |
|
60265928 |
Feb 2001 |
US |
|
60282698 |
Apr 2001 |
US |
|
60288590 |
May 2001 |
US |
|
60294443 |
May 2001 |
US |